Candriam S.C.A. Olema Pharmaceuticals, Inc. Transaction History

Candriam S.C.A.

$16.8 Billion
Q2 2025

A detailed history of Candriam S.C.A. transactions in Olema Pharmaceuticals, Inc. stock. As of the latest transaction made, Candriam S.C.A. holds 850,454 shares of OLMA stock, worth $6.97 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

850,454

Previous 850,517 0.01%

Holding current value

$6.97 Million

Previous $3.2 Million 13.29%

% of portfolio

0.02%

Previous 0.02%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 08, 2025	SELL	$3.06 - $5.62 $192 - $354	-63 Reduced 0.01%	850,454 $3.62 Million
Q1 2025 May 14, 2025	SELL	$3.76 - $6.39 $2.64 Million - $4.48 Million	-701,045 Reduced 45.18%	850,517 $3.2 Million
Q4 2024 Feb 06, 2025	BUY	$5.61 - $12.72 $251,316 - $569,830	44,798 Added 2.97%	1,551,562 $9.05 Million
Q3 2024 Nov 13, 2024	BUY	$10.41 - $16.46 $4.66 Million - $7.38 Million	448,091 Added 42.33%	1,506,764 $18 Million
Q2 2024 Aug 05, 2024	BUY	$8.73 - $13.99 $6.16 Million - $9.87 Million	705,655 Added 199.89%	1,058,673 $11.5 Million
Q1 2024 May 03, 2024	BUY	$10.95 - $16.62 $1.51 Million - $2.29 Million	138,010 Added 64.19%	353,018 $4 Million
Q4 2023 Feb 14, 2024	BUY	$10.53 - $17.14 $2.26 Million - $3.69 Million	215,008 New	215,008 $3.02 Million
Q1 2022 May 13, 2022	SELL	$3.89 - $9.43 $1.29 Million - $3.14 Million	-332,572 Closed	0 $0
Q4 2021 Feb 10, 2022	SELL	$8.75 - $30.71 $87,500 - $307,100	-10,000 Reduced 2.92%	332,572 $3.11 Million
Q3 2021 Nov 09, 2021	SELL	$22.96 - $30.13 $160,720 - $210,910	-7,000 Reduced 2.0%	342,572 $9.44 Million
Q2 2021 Jul 20, 2021	BUY	$21.15 - $36.14 $7.39 Million - $12.6 Million	349,559 Added 2688915.5%	349,572 $9.78 Million
Q1 2021 Apr 29, 2021	BUY	$27.81 - $53.64 $361 - $697	13 New	13 $0

Others Institutions Holding OLMA

# of Institutions

126

Shares Held

68.8M

Call Options Held

Put Options Held

31.4K

View Full List

About Olema Pharmaceuticals, Inc.

Ticker OLMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,419,600
Market Cap $331M
Description
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, local...

More about OLMA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

News

Stay updated on Candriam S.C.A. with notifications on news.

Account